Podcast: The Bio Report

When people think of the potential for artificial intelligence to impact the biopharmaceutical industry, the focus is usually on drug discovery or in the clinic to help guide decision making with regards to pairing the right drug to the right patient.

Yseop is focused on a more administrative use for the technology—the writing of clinical data reports. In this episode of The Bio Report,  Emmanuel Walckenaer, CEO of Yseop, discusses artificial intelligence, its potential to change the way biopharmaceutical companies work in non-obvious ways, and why a large number of biopharmaceutical companies are turning AI to do more with less